Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | Serine/threonine-protein kinase mTOR | ||
Ligand | BDBM50327907 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | ChEMBL_665023 (CHEMBL1260133) | ||
Ki | 0.85±n/a nM | ||
Citation | Liu, KK; Bagrodia, S; Bailey, S; Cheng, H; Chen, H; Gao, L; Greasley, S; Hoffman, JE; Hu, Q; Johnson, TO; Knighton, D; Liu, Z; Marx, MA; Nambu, MD; Ninkovic, S; Pascual, B; Rafidi, K; Rodgers, CM; Smith, GL; Sun, S; Wang, H; Yang, A; Yuan, J; Zou, A 4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors. Bioorg Med Chem Lett20:6096-9 (2010) [PubMed] Article | ||
More Info.: | Get all data from this article, Assay Method | ||
Serine/threonine-protein kinase mTOR | |||
Name: | Serine/threonine-protein kinase mTOR | ||
Synonyms: | FK506-binding protein 12-rapamycin complex-associated protein 1 | FKBP12-rapamycin complex-associated protein | FRAP | FRAP 1 (mTOR) | FRAP1 | FRAP2 | MTOR | MTOR_HUMAN | Mammalian Target of Rapamycin (mTOR) | P42345 | RAFT1 | RAPT1 | Rapamycin and FKBP12 target 1 | Rapamycin target protein | Serine/threonine-protein kinase (mTOR) | mTORC2 | ||
Type: | Rapamycin target protein | ||
Mol. Mass.: | 288917.12 | ||
Organism: | Homo sapiens (Human) | ||
Description: | P42345 | ||
Residue: | 2549 | ||
Sequence: |
| ||
BDBM50327907 | |||
n/a | |||
Name | BDBM50327907 | ||
Synonyms: | CHEMBL1257295 | trans-2-amino-8-(4-hydroxycyclohexyl)-4-methyl-6-(6-methylpyridin-3-yl)pteridin-7(8H)-one | ||
Type | Small organic molecule | ||
Emp. Form. | C19H22N6O2 | ||
Mol. Mass. | 366.417 | ||
SMILES | Cc1ccc(cn1)-c1nc2c(C)nc(N)nc2n([C@H]2CC[C@H](O)CC2)c1=O |r,wU:21.23,wD:18.19,(6.09,-29.48,;4.76,-30.26,;4.77,-31.8,;3.44,-32.58,;2.1,-31.81,;2.09,-30.28,;3.42,-29.5,;.78,-32.59,;-.55,-31.83,;-1.88,-32.6,;-3.22,-31.84,;-3.22,-30.3,;-4.54,-32.61,;-4.55,-34.15,;-5.88,-34.92,;-3.21,-34.92,;-1.88,-34.14,;-.54,-34.91,;-.54,-36.45,;-1.87,-37.22,;-1.87,-38.76,;-.54,-39.53,;-.54,-41.07,;.79,-38.76,;.8,-37.22,;.79,-34.14,;2.13,-34.9,)| | ||
Structure |